← Leaderboards
Karen S Anderson
Yale University
$26,797,421
Attributed
$28,497,845
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,497,845 · 16
By mechanism
R01$23,363,428 · 8
P50$1,742,991 · 2
R37$1,684,624 · 1
R56$1,011,900 · 2
R21$360,365 · 1
P30$332,537 · 1
Top collaborators
- Natalia Issaeva5 shared
- Wendell G Yarbrough5 shared
- Priti Kumar1 shared
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularDesignNovel TherapeuticsPharmaceutical PreparationsToxic EffectDrug ResistanceEvaluationBaseLeadPre-ClinicalAcquired Immunodeficiency SyndromeSiteStructureInhibitor/AntagonistCellsHiv-1Molecular TargetResponseMalignant NeoplasmsSuccessMutationMemberGenomeProperty
Grant awards (82)
Mechanism and Inhibition of HIV Reverse Transcriptase$833,851
R37 · FY2025 · AI · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$850,773
R37 · FY2024 · AI · contact PI
Project 3: Demethylation of HPV-associated head and neck cancer to trigger APOBEC synthetic lethality and enhance immune response$432,279
P50 · FY2024 · DE · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$742,737
R01 · FY2023 · AI · contact PI
Project 3: Demethylation of HPV-associated head and neck cancer to trigger APOBEC synthetic lethality and enhance immune response$437,838
P50 · FY2023 · DE · contact PI
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$404,678
R01 · FY2023 · DE
Mechanism and Inhibition of HIV Reverse Transcriptase$742,737
R01 · FY2022 · AI · contact PI
Project 3: Demethylation of HPV-associated head and neck cancer to trigger APOBEC synthetic lethality and enhance immune response$435,036
P50 · FY2022 · DE · contact PI
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$400,632
R01 · FY2022 · DE
Developmental Therapeutics Research Program$58,257
P30 · FY2022 · CA · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$742,737
R01 · FY2021 · AI · contact PI
Project 3: Demethylation of HPV-associated head and neck cancer to trigger APOBEC synthetic lethality and enhance immune response$437,838
P50 · FY2021 · DE · contact PI
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$404,678
R01 · FY2021 · DE
Developmental Therapeutics Research Program$58,257
P30 · FY2021 · CA · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$742,737
R01 · FY2020 · AI · contact PI
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$404,678
R01 · FY2020 · DE
Developmental Therapeutics Research Program$58,257
P30 · FY2020 · CA · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$618,948
R01 · FY2019 · GM · contact PI
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$487,357
R01 · FY2019 · DE
Exploring Novel Targeting Strategies for AIDS Protozoal Pathogens$454,514
R01 · FY2019 · AI · contact PI
Developmental Therapeutics Research Program$58,257
P30 · FY2019 · CA · contact PI
Developmental Therapeutics Research Program$11,904
P30 · FY2019 · CA · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$618,948
R01 · FY2018 · GM · contact PI
Long-acting combination antiretroviral therapy for HIV-AIDS$598,150
R56 · FY2018 · AI
Exploring Novel Targeting Strategies for AIDS Protozoal Pathogens$455,398
R01 · FY2018 · AI · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$75,000
R01 · FY2018 · GM · contact PI
Developmental Therapeutics Research Program$58,257
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Research Program$11,904
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Research Program$11,904
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Research Program$2,857
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Research Program$2,683
P30 · FY2018 · CA · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$618,948
R01 · FY2017 · GM · contact PI
Exploring Novel Targeting Strategies for AIDS Protozoal Pathogens$456,661
R01 · FY2017 · AI · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$499,305
R01 · FY2016 · GM · contact PI
Exploring Novel Targeting Strategies for AIDS Protozoal Pathogens$457,898
R01 · FY2016 · AI · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$495,301
R01 · FY2015 · GM · contact PI
Exploring Novel Targeting Strategies for AIDS Protozoal Pathogens$475,737
R01 · FY2015 · AI · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$495,301
R01 · FY2014 · GM · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$49,296
R01 · FY2014 · GM · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$477,846
R01 · FY2013 · GM · contact PI
Exploring Novel Targeting Strategies for AIDS Protozoal Pathogens$385,036
R01 · FY2013 · AI · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$517,078
R01 · FY2012 · GM · contact PI
Exploring Novel Targeting Strategies for AIDS Protozoal Pathogens$409,613
R01 · FY2012 · AI · contact PI
Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC$314,248
R01 · FY2012 · CA · contact PI
Exploring Novel Targeting Strategies for AIDS Protozoal Pathogens$409,613
R01 · FY2011 · AI · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$409,051
R01 · FY2011 · GM · contact PI
Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC$314,248
R01 · FY2011 · CA · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$460,783
R01 · FY2010 · GM · contact PI
Exploring Novel Targeting Strategies for AIDS Protozoal Pathogens$413,750
R01 · FY2010 · AI · contact PI
Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC$323,966
R01 · FY2010 · CA · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$452,556
R01 · FY2009 · GM · contact PI
Exploring Novel Targeting Strategies for AIDS Protozoal Pathogens$413,750
R56 · FY2009 · AI · contact PI
Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC$323,966
R01 · FY2009 · CA · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$439,504
R01 · FY2008 · GM · contact PI
Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC$323,395
R01 · FY2008 · CA · contact PI
Novel Approach to Study Transient Enzyme Intermediates$282,538
R01 · FY2008 · GM · contact PI
Universal Technology for Profiling the Dynamics of Normal & Oncogenic Signaling$161,778
R21 · FY2008 · CA · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$401,109
R01 · FY2007 · GM · contact PI
A Molecular Approach For Opportunistic HIV-1 Infections$348,813
R01 · FY2007 · AI · contact PI
Novel Approach to Study Transient Enzyme Intermediates$282,538
R01 · FY2007 · GM · contact PI
Universal Technology for Profiling the Dynamics of Normal & Oncogenic Signaling$198,587
R21 · FY2007 · CA · contact PI
Mechanism and Inhibition of HIV Reverse Transcriptase$442,132
R01 · FY2006 · GM · contact PI
A Molecular Approach For Opportunistic HIV-1 Infections$359,231
R01 · FY2006 · AI · contact PI
Novel Approach to Study Transient Enzyme Intermediates$290,976
R01 · FY2006 · GM · contact PI
A Molecular Approach For Opportunistic HIV-1 Infections$367,875
R01 · FY2005 · AI
Mechanism and Inhibition of HIV Reverse Transcriptase$361,638
R01 · FY2005 · GM
Novel Approach to Study Transient Enzyme Intermediates$297,979
R01 · FY2005 · GM
Mechanism and Inhibition of HIV Reverse Transcriptase$40,877
R01 · FY2005 · GM
Mechanism and Inhibition of HIV Reverse Transcriptase$351,200
R01 · FY2004 · GM
A Molecular Approach For Opportunistic HIV-1 Infections$307,950
R01 · FY2004 · AI
MECHANISM AND INHIBITION OF HIV REVERSE TRANSCRIPTASE$297,243
R01 · FY2003 · GM
MECHANISTIC STUDIES ON PEP UTILIZING ENZYMES$227,884
R01 · FY2003 · GM
MECHANISM AND INHIBITION OF HIV REVERSE TRANSCRIPTASE$288,720
R01 · FY2002 · GM
MECHANISTIC STUDIES ON PEP UTILIZING ENZYMES$227,884
R01 · FY2002 · GM
MECHANISM AND INHIBITION OF HIV REVERSE TRANSCRIPTASE$280,445
R01 · FY2001 · GM
MECHANISTIC STUDIES ON PEP UTILIZING ENZYMES$227,884
R01 · FY2001 · GM
MOLECULAR APPROACH FOR OPPORTUNISTIC HIV INFECTIONS$167,915
R01 · FY2001 · AI
MECHANISM AND INHIBITION OF HIV REVERSE TRANSCRIPTASE$35,000
R01 · FY2001 · GM
Enzymes, Coenzymes, and Metabolic Pathways$2,000
R13 · FY2001 · GM
MECHANISM AND INHIBITION OF HIV REVERSE TRANSCRIPTASE$272,412
R01 · FY2000 · GM
MECHANISTIC STUDIES ON PEP UTILIZING ENZYMES$221,280
R01 · FY2000 · GM
MOLECULAR APPROACH FOR OPPORTUNISTIC HIV INFECTIONS$163,026
R01 · FY2000 · AI